TG Therapeutics reported second quarter 2026 results with total global revenue of approximately $240 million and raised its full year 2026 total global revenue guidance to approximately $950 million. The company also increased its full year BRIUMVI U.S. net product revenue target to between $890 million and $905 million. Second quarter BRIUMVI U.S. net product revenue reached $227.7 million, representing a 64% increase over the prior year period. Net income for the quarter was $7.8 million, compared to $28.2 million in the same period of 2025. The company announced positive Phase 3 ENHANCE data supporting a simplified single-infusion initiation regimen for BRIUMVI and reported positive Phase 1 pharmacokinetic data for a subcutaneous formulation expected to yield top-line results by year-end 2026 or early 2027. TG Therapeutics operates in the biotechnology industry, focusing on the development and commercialization of treatments for immune-mediated diseases.